Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

Key Takeaways Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.CEO Kevin Conroy ...

Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $95 and keeps a Buy rating on the ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product. The analyst ...

The firm's analyst highlighted the solid momentum of Exact Sciences' Cologuard business, noting a Compound Annual Growth Rate (CAGR) of approximately 31% from 2021 to 2023 for the product.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, has announced the company presenting modeling data evaluating the simulated benefit and burden of established CRC ...